Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 2,628,787 unlisted options exercisable at $0.10 each, expiring on November 17, 2029. This acquisition was approved by shareholders at the company’s Annual General Meeting, indicating a strategic move to align the director’s interests with the company’s long-term growth and shareholder value.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is engaged in creating targeted and personalized treatment options to improve patient outcomes in oncology.
Average Trading Volume: 934,319
Technical Sentiment Signal: Hold
Current Market Cap: A$60.99M
See more insights into PTX stock on TipRanks’ Stock Analysis page.